Search Results

You are looking at 41 - 50 of 85 items for :

  • "vemurafenib" x
  • Refine by Access: All x
Clear All
Full access

Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra Stefanovic, Srinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, and Susan D. Darlow

to a promising avenue of targeted therapies for patients with these rare cancers. The phase II VE-BASKET study evaluated the efficacy of BRAF inhibitor vemurafenib. 75 The final efficacy and safety analysis included 26 adults with BRAF V600E

Full access

Daniel P. Kronish and Richard T. Penson

of vemurafenib. 3 Equipoise is not the main justification for an RCT being ethical and, in a pure form, rarely exists. Very rarely with the newer treatments can we explain randomization in RCTs with a coin flip of equitable allocation, or the

Full access

Shumei Kato, Vivek Subbiah, and Razelle Kurzrock

. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis . JAMA Oncol 2016 ; 2 : 1452 – 1459 . 4. Hyman DM Puzanov I Subbiah V . Vemurafenib in

Full access

Axel Grothey

taking this approach in the 8% of patients with BRAF -mutated tumors. These patients typically have poor outcomes and therefore warrant more aggressive treatment. Unfortunately, the BRAF inhibitor vemurafenib has not been proven beneficial in these

Full access

Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin, and Aaron S. Kesselheim

33. Larkin J , Ascierto PA , Dréno B , . Combined vemurafenib and cobimetinib in BRAF-mutated melanoma . N Engl J Med 2014 ; 371 : 1867 – 1876 . 25265494 10.1056/NEJMoa1408868 34. Ribas A , Gonzalez R , Pavlick A , . Combination

Full access

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski

markers is currently limited for advanced thyroid cancers, recent data have shown that the BRAF inhibitors vemurafenib and dabrafenib can be effective treatment options for DTC harboring the BRAF V600E mutation. 54 – 56 Because this mutation is common

Full access

Presenter: Ronald S. Go

to vemurafenib; this is the only drug approved by the FDA for all histiocytoses. Those with MAPK pathway gene mutations may benefit from treatment with cobimetinib or other MEK inhibitors. Based on the guidelines, cladribine and pegylated interferon

Full access

Presenters: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

, demonstrated improved overall survival (median, 33.6 vs 16.9 months), progression-free survival (median, 14.9 vs 7.3 months), and overall response rate (64% vs 41%) compared with vemurafenib. 6 “There are very active options for patients with metastatic

Full access

Philip E. Lammers, Christine M. Lovly, and Leora Horn

may prove fruitful in NSCLC. Dabrafenib, a BRAF inhibitor, showed activity in 17 patients with BRAF V600E mutations, 9 and case reports have documented responses of BRAF -mutant lung cancer to the BRAF inhibitor vemurafenib. 10 In addition

Full access

James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos

small molecule BRAF inhibitor vemurafenib. 7 , 10 The newer BRAF inhibitor dabrafenib has also been approved for use in melanoma. This report presents the first case of the cooccurrence of malignant melanoma and HCL, both harboring the BRAF p